Endo (ENDPQ) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from passionate team members around the globe collaborating to bring the best treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them.

On August 17, 2022, Nasdaq commenced customary delisting procedures due to the Company’s filing of Chapter 11 proceedings. On August 26, 2022, Nasdaq suspended trading in the Company’s common stock. As a result of the suspension and expected delisting, the Company’s common stock began trading exclusively on the over-the-counter market under the symbol ENDPQ on August 26.

Remarks Regarding Chapter 11 Settlement in Principle